Core Insights - The company reported a revenue of 6.016 billion yuan for the first half of 2025, representing a year-on-year growth of 12.79% [1] - The net profit attributable to shareholders reached 998 million yuan, with a year-on-year increase of 5.03% [1] - The company plans to distribute a cash dividend of 1.3 yuan per 10 shares, totaling 107 million yuan, to reward shareholders [1] Financial Performance - Research and development investment amounted to 1.14 billion yuan, reflecting a year-on-year growth of 12.09%, with an R&D expense ratio of 12.74% [2] - The company filed over 260 new patent applications during the reporting period, focusing on next-generation platform technologies [2] - Cumulative patent applications exceeded 9,700, with over 80% being invention patents [2] Product Development and Innovation - The company has received FDA approval for over 20 AI-enabled devices, positioning it among the industry leaders [2] - The uIPW intelligent radiation therapy system received regulatory approval, marking a significant advancement in standardized and precise intelligent radiation therapy in China [2] - The uCT SiriuX, a dual-source CT system, was included in the special review channel for innovative medical devices, showcasing advanced motion artifact correction capabilities [3] Industry Trends and Regulatory Environment - Recent policy initiatives from the National Medical Products Administration aim to support innovation in high-end medical equipment and AI medical devices [3] - The focus on optimizing the regulatory framework for high-end medical imaging equipment is expected to enhance the global competitiveness of Chinese medical device companies [3]